Cassava Sciences stock (US14817C1071): Nasdaq-listed Alzheimer’s developer trades around USD 1.36 after recent volatility

Cassava Sciences shares, now trading on Nasdaq under the ticker FLNA, changed hands at about USD 1.36 on 06/03/2026 as the biotech continues to work on late-stage Alzheimer’s drug candidates amid heightened investor scrutiny.

Cassava Sciences stock, which is listed on Nasdaq in the United States under the ticker FLNA, last closed at about USD 1.36 on 06/03/2026 according to MarketBeat, reflecting ongoing volatility as the biotech advances its Alzheimer’s program and responds to intense investor attention.MarketBeat as of 06/03/2026

As a U.S.-based clinical-stage biopharmaceutical company, Cassava Sciences focuses on developing drug candidates targeting neurodegenerative diseases, and its shares remain closely watched on Nasdaq as the company navigates clinical development and regulatory expectations.Cassava Sciences investor relations as of 05/2026

As of: 04/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: SAVA
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Austin, United States
• Core markets: United States and global neurology markets
• Key revenue drivers: Future potential sales of Alzheimer’s and neurodegenerative disease therapies, contingent on successful trials and approvals
• Home exchange/listing venue: Nasdaq (FLNA)
• Trading currency: USD

Cassava Sciences: core business model

Cassava Sciences centers its business on discovering and developing drug candidates aimed at diseases of the nervous system, with its economic prospects tied mainly to successfully bringing Alzheimer’s-focused therapies through clinical trials and onto the market.

Industry trends and competitive position

The broader Alzheimer’s drug market has drawn significant attention in recent years as large pharmaceutical groups and specialist biotechs invest heavily in disease-modifying therapies, with several monoclonal antibody treatments and other mechanisms moving through late-stage trials and regulatory reviews, which sets a competitive backdrop for Cassava Sciences as of mid-2026.S&P Global sector overview as of 04/2026

Within this environment, Cassava Sciences competes against much larger companies that often have diversified pipelines and commercial infrastructures, meaning that outcomes of its key clinical studies and any future regulatory decisions could have an outsized impact on its valuation compared with more diversified peers.

Conclusion

Cassava Sciences remains a closely followed Nasdaq biotechnology name as investors monitor its clinical efforts in Alzheimer’s disease alongside a share price that recently stood near USD 1.36 as of 06/03/2026. The company’s position in a competitive neurodegenerative-disease landscape means future data and regulatory milestones could be important catalysts for sentiment. For now, the stock continues to trade as a higher-risk, development-stage biotech within the broader U.S. healthcare sector.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.